English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90069/105176 (86%)
Visitors : 6600198      Online Users : 593
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/16194


    Title: JNK suppression is essential for 17b-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells
    Authors: 黃志揚;HUANG, CHIH-YANG
    Contributors: 生物科技學系
    Keywords: CANCER cells;MIGRATION & immigration;CELL migration;COLON (Anatomy) -- Cancer;ESTRADIOL;PROTEOLYTIC enzymes
    Date: 2011
    Issue Date: 2012-11-23 17:09:46 (UTC+8)
    Abstract: "Background: Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in
    women are lower than in men. However, it is unknown if 17b-estradiol treatment is sufficient to inhibit
    prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells.
    Methods: We analyzed the protein expression of urokinase plasminogen activator (uPA), tissue plasminogen
    activator (tPA), matrix metallopeptidases (MMPs), plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of
    metalloproteinases (TIMPs), and the cellular motility in PGE2-stimulated human LoVo cells. 17b-Estradiol and the
    inhibitors including LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor),
    SP600125 (JNK1/2 inhibitor), QNZ (NF B inhibitor) and ICI 182 780 were further used to explore the inhibitory
    effects of 17b-estradiol on PGE2-induced LoVo cell motility. Student’s t-test was used to analyze the difference
    between the two groups.
    Results: Upregulation of urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and matrix
    metallopeptidases (MMPs) is reported to associate with the development of cancer cell mobility, metastasis, and
    subsequent malignant tumor. After administration of inhibitors including LY294002, U0126, SB203580, SP600125 or
    QNZ, we found that PGE2 treatment up-regulated uPA and MMP-9 expression via JNK1/2 signaling pathway, thus
    promoting cellular motility in human LoVo cancer cells. However, PGE2 treatment showed no effects on regulating
    expression of tPA, MMP-2, plasminogen activator inhibitor-1 (PAI-1), tissue inhibitor of metalloproteinase-1, -2, -3
    and -4 (TIMP-1, -2, -3 and -4). We further observed that 17b-estradiol treatment inhibited PGE2-induced uPA, MMP-
    9 and cellular motility by suppressing activation of JNK1/2 in human LoVo cancer cells.
    Conclusions: Collectively, these results suggest that 17b-estradiol treatment significantly inhibits PGE2-induced
    motility of human LoVo colon cancer cells."
    Relation: JOURNAL OF BIOMEDICAL SCIENCE
    Appears in Collections:[生物科技學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML110View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback